Abstract
Mutated forms of p53 are often expressed in a variety of human tumors. In addition to loss of function of the p53 tumor suppressor, mutant p53s contribute to malignant process by acquisition of novel functions that enhance transformed properties of cells and resistance to anticancer therapy in vitro, and increase tumorigenecity, invasiveness and metastatic ability in vivo. Searching for genes that change expression in response to p53 gain of function mutants may give a clue to the mechanisms underlying their oncogenic effects. Recently by subtraction hybridization cloning we found that the dUTPase gene is transcriptionally upregulated in p53-null mouse fibroblasts expressing the exogenous human tumor-derived His175 p53 mutant. Here we show that conditional expression of His175 and Trp248 hot-spot p53 mutants in p53-negative mouse 10(1) fibroblasts and human SK-OV3 and H1299 tumor cells results in increase in dUTPase gene transcription, an important marker predicting the efficacy of cancer therapy with fluoropyrimidine drugs. Using tetracycline-regulated retroviral vectors for conditional expression of p53 mutants, we found that transcription of the dUTPase gene is increased within 24 h after tetracycline withdrawal, and the cells acquire higher resistance to 5-FU. Additional inactivation of the N-terminal transcription activation domain of mutant p53 (substitutions in amino-acid residues 22 and 23) results in abrogation of both induction of dUTPase transcripts and 5-FU resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aherne GW, Browne S . 1999 Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy Jackman AL (ed) Totowa, NJ: Humana Press, Inc pp 409–421
Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC . 1996 Int. J. Cancer 69: 190–192
Blandino G, Levine AJ, Oren M . 1999 Oncogene 18: 477–485
Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L . 2000 Clin. Cancer Res. 6: 2751–2758
Bunz L, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B . 1999 J. Clin. Invest. 104: 263–269
Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P . 2000 J. Clin. Oncol. 18: 1465–1473
Canman CE, Radany EH, Parsels LA, Davis MA, Lawrence TS, Maybaum J . 1994 Cancer Res. 54: 2296–2298
Chin KV, Ueda K, Pastan I, Gottesman MM . 1992 Science 255: 459–462
Deb S, Jackson CT, Subler MA, Martin DW . 1992 J. Virol. 66: 6164–6170
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ . 1993 Nat. Genet. 4: 42–46
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A . 1992 Nature 356: 215–221
el-Deiry WS . 1998 Semin. Cancer Biol. 8: 345–357
Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP . 1998 Mol. Cell. Biol. 18: 3735–3743
Gloushankova N, Ossovskaya V, Vasiliev J, Chumakov P, Kopnin B . 1997 Oncogene 15: 2985–2989
Gossen M, Bujard H . 1992 Proc. Natl. Acad. Sci. USA 89: 5547–5551
Greenblatt MS, Bennett WP, Hollstein M, Harris CC . 1994 Cancer Res. 54: 4855–4878
Harvey DM, Levine AJ . 1991 Genes Dev. 5: 2375–2385
Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M . 1994 Am. J. Pathol. 145: 702–714
Kelavkar UP, Badr KF . 1999 Proc. Natl. Acad. Sci. USA 96: 4378–4383
Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya VS, Pugacheva EN, Rybalkina EY, Khokhlova OA, Chumakov PM . 1995 Oncol. Res. 7: 299–306
Kremenetskaya OS, Logacheva NP, Baryshnikov AY, Chumakov PM, Kopnin BP . 1997 Oncol. Res. 9: 155–166
Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, Stoehlmacher J, Lenz HJ . 2000 Cancer Res. 60: 3493–3503
Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S . 1998 Oncogene 16: 3169–3176
Levine AJ . 1997 Cell 88: 323–331
Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB . 1995 Ann. NY Acad. Sci. 768: 111–128
Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V . 1998 Oncogene 16: 3269–3277
Lin J, Teresky AK, Levine AJ . 1995 Oncogene 10: 2387–2390
Lindhal T . 1982 Annu. Rev. Biochem. 51: 61–87
Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G . 2000 Proc. Natl. Acad. Sci. USA 97: 4174–4179
Lotem J, Sachs L . 1995 Proc. Natl. Acad. Sci. USA 92: 9672–9676
Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V . 2001 EMBO J. 20: 4163–4172
Michalovitz D, Halevy O, Oren M . 1991 J. Cell Biochem. 45: 22–29
Peled A, Zipori D, Rotter V . 1996 Cancer Res. 56: 2148–2156
Pugacheva EN, Snegur IN, Kopnin BP, Chumakov PM . 2000 Mol. Biol. 34: 143–151
Sambrook J, Fritsch E, Maniatis T . 1989 Molecular Cloning New York: Cold Spring Harbor Laboratory Press
Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M, Haupt Y . 1999 J. Biol. Chem. 274: 8371–8374
Sun Y, Nakamura K, Wendel E, Colburn N . 1993 Proc. Natl. Acad. Sci. USA 90: 2827–2831
Tsutsumi-Ishii Y, Tadokoro K, Hanaoka F, Tsuchida N . 1995 Cell Growth Differ. 6: 1–8
Wolf D, Harris N, Rotter V . 1984 Cell 38: 119–126
Yang X, Pater A, Tang SC . 1999 Oncogene 18: 4546–4553
Zheng M, Wang H, Zhang H, Ou Q, Shen B, Li N, Yu B . 1999 J. Cancer Res. Clin. Oncol. 125: 357–360
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pugacheva, E., Ivanov, A., Kravchenko, J. et al. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 21, 4595–4600 (2002). https://doi.org/10.1038/sj.onc.1205704
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205704
Keywords
This article is cited by
-
Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells
Cancer Gene Therapy (2022)
-
Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells
Journal of Experimental & Clinical Cancer Research (2019)
-
Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells
Scientific Reports (2017)
-
Predictive biomarkers in precision medicine and drug development against lung cancer
Chinese Journal of Cancer (2015)
-
When mutants gain new powers: news from the mutant p53 field
Nature Reviews Cancer (2009)